Nav: Home

Detecting blood clot risk using biomarkers

March 15, 2017

Cancer is one of the hardest medical conditions to overcome, and for those who do so, the battle often does not stop at remission. Many cancers predispose patients to develop blood clots, particularly patients who are diagnosed at a late stage, which often complicates their treatment and reduces survival rates.

These blood clots can become dislodged, and if a clot travels to the lungs, it can cause immediate distress and puts a patient at a high risk of death. In the United States, blood clots affect between 300,000 and 600,000 people each year and approximately 60,000 to 100,000 of those individuals will die, according to the Centers for Disease Control and Prevention.

Researchers at Boston Medical Center (BMC) and Boston University School of Medicine (BUSM) aim to increase survival rates among these patients by identifying new and validating existing biomarkers, or substances in the blood, that indicate if a patient is at high risk for developing a clot. Patients at BMC who are newly diagnosed with cancer will be asked if they would like to donate their blood for the study. The researchers will test the blood samples for biomarkers that may indicate whether a person has a high risk for blood clots.

This collection of blood samples will be part of a comprehensive study of thrombosis biomarkers from populations who are currently underrepresented in biobanking projects and clinical research studies. Approximately 59 percent of BMC patients come from underserved populations. Many of BMC's patients present to the hospital with more advanced disease due to challenging access to health care or cancer screening.

"Identifying and standardizing biomarkers may provide clinicians with important information to improve patient care," said Chris Andry, MPhil, PhD, vice chair for operations and management and administrative director for pathology and laboratory medicine at BMC, who will lead the study in collaboration with co-investigators Debbie Stearns-Kurosawa, PhD, associate professor of pathology and laboratory medicine and co-director of the Coagulation Research Laboratory (BUSM), and Mark Sloan, MD, a physician in hematology and oncology at BMC and assistant professor of medicine at BUSM.

Additionally, it is challenging for researchers to know if they have accurately measured the biomarkers, taking into account all the variables such as time to assay or temperature changes that may impact how the blood markers are measured. This study will deliberately evaluate these variables to assist with guideline development for hospital laboratories to use when testing these biomarkers.

"Once we see how these biomarkers stand against time, we can determine appropriate timelines for clinical assessments to ensure that they are as accurate as possible in identifying risk," said Andry, who also is associate professor of pathology and laboratory medicine at BUSM. "This information, in combination with patient education, has the potential to increase survival rates by being able to proactively treat these patients for blood clots."
This project is funded by NCI Contract No. HHSN261200800001E.

Boston University Medical Center

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...